Literature DB >> 32236408

Clinical Evolution of AmpC-Mediated Ceftazidime-Avibactam and Cefiderocol Resistance in Enterobacter cloacae Complex Following Exposure to Cefepime.

Ryan K Shields1,2, Alina Iovleva1, Ellen G Kline1, Akito Kawai3,4, Christi L McElheny1, Yohei Doi1,2,3,4.   

Abstract

We report 2 independent patients from whom carbapenem and ceftazidime-avibactam-resistant Enterobacter cloacae complex strains were identified. The ceftazidime-avibactam resistance was attributed to a 2-amino acid deletion in the R2 loop of AmpC β-lactamase, which concurrently caused resistance to cefepime and reduced susceptibility to cefiderocol, a novel siderophore cephalosporin.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  R2 loop; cefepime; deletion; β-lactamase

Year:  2020        PMID： 32236408      PMCID： PMC7744991          DOI： 10.1093/cid/ciaa355

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  20 in total

Review 1.  Gain and loss of antibiotic resistant genes in multidrug resistant bacteria: One Health perspective.

Authors:  Misung Kim; Jaeeun Park; Mingyeong Kang; Jihye Yang; Woojun Park
Journal:  J Microbiol       Date:  2021-04-20       Impact factor: 3.422

2.  Defining Baseline Mechanisms of Cefiderocol Resistance in the Enterobacterales.

Authors:  Patricia J Simner; Stephan Beisken; Yehudit Bergman; Michael Ante; Andreas E Posch; Pranita D Tamma
Journal:  Microb Drug Resist       Date:  2021-10-06       Impact factor: 3.431

3.  In vitro activity of cefiderocol against ceftazidime-avibactam susceptible and resistant KPC-producing Enterobacterales: cross-resistance and synergistic effects.

Authors:  Gabriele Bianco; Matteo Boattini; Sara Comini; Marco Iannaccone; Alessandro Bondi; Rossana Cavallo; Cristina Costa
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-08-31       Impact factor: 3.267

Review 4.  Cefiderocol: Systematic Review of Mechanisms of Resistance, Heteroresistance and In Vivo Emergence of Resistance.

Authors:  Stamatis Karakonstantis; Maria Rousaki; Evangelos I Kritsotakis
Journal:  Antibiotics (Basel)       Date:  2022-05-27

Review 5.  Antimicrobial Treatment Options for Difficult-to-Treat Resistant Gram-Negative Bacteria Causing Cystitis, Pyelonephritis, and Prostatitis: A Narrative Review.

Authors:  Andrew Chou; Elwyn Welch; Andrew Hunter; Barbara W Trautner
Journal:  Drugs       Date:  2022-03-14       Impact factor: 11.431

6.  Progressive Development of Cefiderocol Resistance in Escherichia coli During Therapy is Associated With an Increase in blaNDM-5 Copy Number and Gene Expression.

Authors:  Patricia J Simner; Heba H Mostafa; Yehudit Bergman; Michael Ante; Tsigereda Tekle; Ayomikun Adebayo; Stephan Beisken; Kathryn Dzintars; Pranita D Tamma
Journal:  Clin Infect Dis       Date:  2022-08-24       Impact factor: 20.999

7.  Is Ceftazidime/Avibactam an Option for Serious Infections Due to Extended-Spectrum-β-Lactamase- and AmpC-Producing Enterobacterales?: a Systematic Review and Meta-analysis.

Authors:  Burcu Isler; Yukiko Ezure; Jose Luis García-Fogeda Romero; Patrick Harris; Adam G Stewart; David L Paterson
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

Review 8.  New Perspectives on Antimicrobial Agents: Cefiderocol.

Authors:  Erin K McCreary; Emily L Heil; Pranita D Tamma
Journal:  Antimicrob Agents Chemother       Date:  2021-07-16       Impact factor: 5.191

9.  Evolution of Cefiderocol Non-Susceptibility in Pseudomonas aeruginosa in a Patient Without Previous Exposure to the Antibiotic.

Authors:  Ana Paula Streling; Mohanad M Al Obaidi; William D Lainhart; Tirdad Zangeneh; Ayesha Khan; An Q Dinh; Blake Hanson; Cesar A Arias; William R Miller
Journal:  Clin Infect Dis       Date:  2021-12-06       Impact factor: 9.079

10.  Cefiderocol Activity Against Clinical Pseudomonas aeruginosa Isolates Exhibiting Ceftolozane-Tazobactam Resistance.

Authors:  Patricia J Simner; Stephan Beisken; Yehudit Bergman; Andreas E Posch; Sara E Cosgrove; Pranita D Tamma
Journal:  Open Forum Infect Dis       Date:  2021-06-12       Impact factor: 3.835
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.